Takahashi, Masato
Sapporo National Hospital
7 papers on CoChatORCID 0000-0002-6641-9598
Most cited papers
- Verified
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine
Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers
Cited by 3,270
- Verified
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine
Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer
Cited by 2,622
- Verified
Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation
Infective Endocarditis Diagnosis and ManagementStreptococcal Infections and Treatments
Cited by 1,707
- Verified
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology
Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer
Cited by 624
- Verified
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 604
- Verified
Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines
Hamaguchi, J., Nakagawa, H., Takahashi, M., Kudo, T., Kamiyama, N., Sun, B., Oshima, T., Sato, Y., Deguchi, K., Todo, S., et al. (2007) · Molecular Cancer
Glycosylation and Glycoproteins ResearchDrug Transport and Resistance Mechanisms
Cited by 45
- Verified
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
Takahashi, S., Karayama, M., Takahashi, M., Watanabe, J., Minami, H., Yamamoto, N., Kinoshita, I., Lin, C.-C., Im, Y.-H., Achiwa, I., et al. (2021) · Clinical Cancer Research
HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism
Cited by 37
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free